Recombinant Human SP-D Production for Yield and Oligomer Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing recombinant human surfactant protein D (rhSP-D) face challenges in achieving sufficient yields and consistent oligomerization states, which are crucial for therapeutic efficacy, particularly in treating pulmonary diseases.
Innovation Solution
A method involving the expression of human SP-D in human myeloid leukemia cell lines, such as NM-H9D8, using specific expression vectors and culturing conditions to achieve high yields of SP-D with controlled oligomerization, including the use of antifolates like methotrexate and perfusion bioreactors, followed by purification using Q-Sepharose and Superdex 75 columns.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If traditional isolation methods from bronchoalveolar lavage or amniotic fluid are used, then natural SP-D can be obtained, but most SP-D is lost during purification due to hydrophilic properties
Solution Approach 1:
The patent changes the production system from natural isolation to recombinant expression in mammalian cells, fundamentally altering how SP-D is obtained. This approach produces SP-D in a controlled environment where purification can be optimized, directly addressing the loss issue during purification while dramatically increasing yield.
Solution Approach 2:
Instead of isolating SP-D from natural sources, the patent uses recombinant DNA technology to copy and express the SP-D gene in mammalian cells. This creates a renewable source of SP-D that can be produced in large quantities and purified using optimized protocols, eliminating the limitations of natural source isolation.
2Productivity
If recombinant human SP-D is produced in commonly used mammalian cell lines, then large-scale production is possible, but yields are typically insufficient for commercial campaigns
Solution Approach 1:
The patent optimizes multiple parameters including cell line selection (CHO or HEK 293), transfection methods, culture conditions, and harvest timing to maximize SP-D yield. These parameter optimizations transform the production system from low-yield research scale to commercially viable production scale.
Solution Approach 2:
The patent implements continuous or repeated batch culture systems where cells are maintained in production mode for extended periods, allowing continuous accumulation of SP-D. This approach maximizes productivity by keeping the production system actively generating SP-D without interruption or downtime.
3Ease of manufacture
If SP-D is produced without controlled oligomerization, then production is simpler, but consistent oligomerization states are not achieved which are crucial for therapeutic efficacy
Solution Approach 1:
The patent controls oligomerization by optimizing expression conditions, protein concentration, and purification parameters. By carefully controlling these parameters, the system produces SP-D in consistent oligomeric states (trimers, hexamers, or higher) that are therapeutically active, without complicating the manufacturing process.
Solution Approach 2:
The patent uses specific purification resins and conditions that act as intermediaries to select for properly oligomerized SP-D. These purification tools preferentially bind or separate oligomeric forms, ensuring that only therapeutically active oligomers are collected while maintaining manufacturing simplicity.
4Reliability
If higher-order multimerization of SP-D is increased, then the number of SP-D-binding sites to carbohydrate ligands increases achieving potent bacterial and viral agglutination effects, but production and purification become more challenging
Solution Approach 1:
The patent controls the degree of oligomerization by adjusting expression parameters and purification conditions to produce the desired higher-order multimers. This approach ensures therapeutic efficiency through increased binding sites while managing production complexity through optimized protocols.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method significantly enhances SP-D production yields and stabilizes higher-order oligomeric forms like dodecamers, improving the therapeutic potential of SP-D formulations by up to 5-15-fold and reducing larger oligomeric species, ensuring consistent and effective pulmonary surfactant compositions.
Implementation Method 1
purification using Q-Sepharose and Superdex 75 columns
Implementation Method 2
purification using Q-Sepharose and Superdex 75 columns
Data Source
AI summary
Some embodiments of the methods and compositions provided herein relate to the preparation surfactant protein-D (SP-D). Some embodiments include the expression of human SP-D in certain cell lines, and the purification of human SP-D from such cell lines. Some embodiments include the preparation of certain oligomeric forms of human SP-D.